PITTSBURGH and TORONTO — January 27, 2026 — Leads & Copy — Sharp Therapeutics Corp. (TSX-V: SHRX) (OTCQB: SHRXF), a biotechnology company focused on developing small-molecule therapeutics for genetic diseases, has appointed Robin Ely, M.D., Clinical Director and co-founder of the National Gaucher Foundation (NGF), to its Advisory Board.
Dr. Ely co-founded NGF in 1984 after her son was diagnosed with Gaucher disease and was pivotal in facilitating the U.S. FDA studies and approval of Ceredase, the first enzyme replacement therapy for Gaucher disease. She also directs the Foundation’s Global Diagnostic and Treatment Initiative. Her clinical research on the management of Gaucher disease is internationally recognized.
“We invited Dr. Ely to join our Advisory Board because her clinical experience and patient advocacy background align directly with Sharp’s efforts in orphan diseases, especially Gaucher disease,” said Scott Sneddon, Ph.D., J.D., Chief Executive Officer of Sharp Therapeutics.
Dr. Ely will bring insights to the company’s upcoming Phase 1 study and future registrational development activities as Sharp prepares to initiate clinical studies later this year. Sharp’s mission is to develop medicines that restore function and improve the lives of patients with genetic diseases. They have ‘901 for Gaucher disease and a pipeline of programs in other genetically defined indications, with the goal of delivering transformative therapies for patients.
Dr. Ely joins other advisors on the Sharp Advisory Board, including:
Mark Goldberg, M.D., an expert in developing and commercializing therapies for rare diseases. He previously served as SVP of Clinical Development at Genzyme where he played a central role in the development and regulatory approval of benchmark enzyme replacement therapies, including Fabrazyme® for Fabry disease, Aldurazyme® for MPS I, and Myozyme® and Lumizyme® for Pompe disease. Following Genzyme, Dr. Goldberg served as Senior Vice President and then Executive Vice President of Global Medical and Regulatory Strategy at Synageva BioPharma, where he played a key role in the development and approval of Kanuma® (sebelipase alfa), an enzyme replacement therapy for lysosomal acid lipase deficiency (LALD), leading to the acquisition of Synageva by Alexion for $8.4B. He has also served on the executive team and board of multiple biopharma companies, including ImmunoGen, GlycoMimetics, Blueprint Medicines, Avacta Group, and Walden Biosciences.
Blaine McKee, Ph.D., President and Chief Executive Officer of Walden Biosciences. Dr. McKee has over 25 years of experience with expertise in corporate strategy and business development. He previously served as EVP and Chief Business Officer at ImmunoGen, where he led corporate development, alliance management, commercial assessment, and valuation functions. Before ImmunoGen, Dr. McKee was Head of Corporate Development at Shire, leading corporate strategy, M&A, and licensing. At Shire, he oversaw numerous transactions bringing key therapies into the Shire portfolio. His earlier career included a 15-year tenure at Genzyme, where he rose to SVP of Strategic Development for Transplant, Oncology, and Multiple Sclerosis, leading business development and strategic transactions across multiple therapeutic areas.
Sharp Therapeutics is a preclinical-stage company developing first-choice small-molecule therapeutics for genetic diseases. The Company’s discovery platform produces small molecule compounds that restore activity in mutated proteins giving the potential to treat genetic disorders with conventional pill-based medicines.
Source: Sharp Therapeutics Corp.
